Zoetis Inc. (NYSE:ZTS) Given Average Rating of "Hold" by Brokerages

Key Points

• Zoetis has a consensus “Hold” rating from 19 brokerages: nine analysts rate it Hold, eight Buy, and two Sell. The average 12-month price target is $107.43.
• Several analysts recently lowered their price targets, including BNP Paribas Exane to $110, Citigroup to $96, and HSBC to $95, while maintaining positive or neutral ratings.
• Shares opened at $75.70, near their 12-month low, despite Zoetis slightly exceeding quarterly earnings expectations with $1.87 EPS. Institutional investors own approximately 92.8% of the company’s stock.

Shares of Zoetis Inc. (NYSE:ZTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nineteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $107.4286.

Several analysts have issued reports on the stock. BNP Paribas Exane lowered their price objective on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating for the company in a research report on Tuesday, August 11th. Citigroup reduced their target price on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. HSBC decreased their target price on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research note on Monday, July 6th. William Blair reaffirmed a "market perform" rating on shares of Zoetis in a research note on Thursday, August 6th. Finally, Argus reissued a "hold" rating on shares of Zoetis in a research report on Wednesday, May 27th.

Zoetis Stock Down 0.8%

Shares of NYSE ZTS opened at $75.70 on Friday. The stock has a fifty day moving average price of $75.53 and a 200 day moving average price of $93.85. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis has a 12-month low of $71.00 and a 12-month high of $155.15. The company has a market cap of $31.28 billion, a P/E ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the business earned $1.76 earnings per share. The company's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts anticipate that Zoetis will post 6.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System boosted its stake in shares of Zoetis by 6,680.3% during the 2nd quarter. California State Teachers Retirement System now owns 47,745,365 shares of the company's stock valued at $3,430,982,000 after buying an additional 47,041,186 shares during the last quarter. J. Stern & Co. LLP increased its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock worth $3,028,423,000 after buying an additional 23,877,416 shares during the last quarter. Norges Bank acquired a new stake in Zoetis in the fourth quarter valued at $734,425,000. Flossbach Von Storch SE acquired a new stake in Zoetis in the second quarter valued at $302,601,000. Finally, BlackRock Inc. boosted its stake in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source